Oxford BioMedica
Discover Realise
OXB Laboratory

Our history

Oxford BioMedica was formed out of Oxford University. Oxford BioMedica is now a leading company in gene and cell therapy with 20 years of expertise in gene and cell therapy. As a pioneer in the international field, Oxford BioMedica was the first Company to deliver a gene therapy directly in to the human eye and brain and this means we now have the knowledge and ability to harness our technologies to bring life changing treatment to patients.

Click here to download our corporate fact sheet.

  • 1995

    Oxford BioMedica was founded in 1995 by Professors Alan and Sue Kingsman from the University of Oxford's Department of Biochemistry.

  • 1996

    December: initial public offering (IPO) on the alternative investment market (AIM) of the London Stock Exchange.

  • 2000

    October: UK Gene Therapy Advisory Committee (GTAC) approval received for TroVax® (now OXB-301) to enter clinical development.

  • 2001

    January: new collaboration with Wyeth (acquired by Pfizer in 2009) for development of a 5T4-targeted antibody therapy.

    February: first patient treated with TroVax® (now OXB-301) in a Phase I study in colorectal cancer.

    April: Oxford BioMedica moved to the main market of the London Stock Exchange.

  • 2007

    March: acquisition of Oxxon therapeutics Limited.

    March: global licensing agreement with Sanofi for TroVax® (now OXB-301); upfront payment of US$39 million with potential for a total of US$690 million subject to certain project objectives.

    July: Oxford BioMedica secures rights to endostatin and angiostatin genes from Children's Hospital Boston.

    December: initiation of Phase I/II study for ProSavin® (now OXB-101) in Parkinson's disease.

  • 2009

    April: Oxford BioMedica regains rights to TroVax®.

    April: new collbaroation with Sanofi to develop four novel, gene-based therapies for ocular disease; US$26 million upfront payment with US$24 million committed funding for Phase I/II development.

    December: SAR 422459 received orphan designation from the Committee for Orphan Medicinal Products of the EMA.

  • 2010

    January: SAR 421869 received orphan designation from the Committee for Orphan Medicinal Products of the EMA.

    July: Oxford BioMedica and VIB-K.U.Leuven enter new collaboration funded by the Motor Neurone Disease Association to develop MoNuDin® for Amyotrophic Lateral Sclerosis.

    August: licensing agreement with Emergent BioSolutions Inc.

    November: RetinoStat® (now OXB-201) IND application approved by the FDA for a Phase I/II clinical trial in neovascular “wet” age-related macular degeneration (AMD).

  • 2011

    February: acquisition of a manufacturing facility in Cowley, Oxford.

    March: SAR 422459 IND application approved by the FDA for a Phase I/II clinical trial in Stargardt disease.

    June: new 5T4 antibody research collaboration with ImaginAb.

    October: SAR 421869 IND application approved by the FDA for a Phase I/II clinical trial in Usher syndrome type 1B.

    October: new R&D collaboration with Mayo Clinic to develop a novel gene therapy for the treatment of chronic glaucoma.

  • 2012

    April: ProSavin® (now OXB-101) Phase I/II study met primary endpoints.

    June: MHRA approval received to enable GMP manufacturing for clinical supply.

    June: Sanofi acquires exclusive worldwide rights to develop and commercialise SAR 422459 and SAR 421869 for a total option exercise payment of US$3 million.

    September: new collaboration with Immune Design Corp.

  • 2013

    March: Initiation of Phase II collaborative study for TroVax® (now OXB-301) in Mesothelioma.

    May: Lentiviral Vector Development and Manufacturing Collaboration.

    July: Pre-clinical collaboration with Mayo clinic to treat glaucoma is on track.

    August: $1 million Milestone Payment from Pfizer triggered by entry of PF-06263507, a 5T4-targeted investigational antibody therapy into human trials.

    September: Funding award of £7.7 million under the UK Government's Advanced Manufacturing Supply Chain Initiative.

    October: Agreement from FDA and ANSM to Resume Recruitment into Ocular Clinical Trials.

    December: Option agreement with GlaxoSmithKline for non-exclusive licence using LentiVector® platform technology patents in the development and commercialisation of up to six products targeting rare orphan diseases.

  • 2014

    January: Publication of ProSavin® Phase I/II Study in The Lancet.

    April: Oxford BioMedica completes patient recruitment into RetinoStat® (now OXB-201) Phase I trial.

    May: Oxford BioMedica successfully raises £21.6 million (before expenses) through a Firm Fundraising and Open Offer.

    October: Major new licensing and manufacturing contract with Novartis.

    October: New headquarters and laboratories acquired totalling 6,684 sq m.


Our strategy

Is aligned with the shift from blockbuster model to personalised healthcare, specialty medicines and innovative, targeted therapeutics to solve unmet medical needs

Our mission

Is to build a leading, profitable biopharmaceutical company founded on the successful development and commercialisation of breakthrough gene-based medicines